Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Toxoplasmosis Infection Linked With Neurodegenerative Diseases

XTALKS VITALS NEWS

Neuron

According to the current study, toxoplasmosis may also be associated with the development of neurodegenerative diseases.

Share this!

June 13, 2016 | by Sarah Massey, M.Sc.

According to a new study conducted by researchers at the University of California-Riverside, infection with toxoplasmosis triggers an accumulation of the neurotransmitter glutamate in the brain, which could cause neurodegenerative diseases in predisposed individuals. The results of the research were published in the journal, PLOS Pathogens.

Tweet: #Toxoplasmosis triggers changes which cause #neurodegenerativedisease http://ctt.ec/2kaB9+

Toxoplasmosis is caused by the relatively-common parasite, Toxoplasmosis gondii. While it’s estimated that 60 million people in the US are infected with the parasite, a healthy immune system is usually sufficient to avoid experiencing symptoms.

Complications of toxoplasmosis – including damage to the eyes and brain – usually only occur in immunocompromised individuals. According to the current study however, toxoplasmosis may also be associated with the development of neurodegenerative diseases.

Researchers, led by Emma Wilson - an associate professor in the Division of Biomedical Sciences at the UC-Riverside School of Medicine, came to this conclusion after studying the effects of toxoplasmosis on glutamate production in the brain. Glutamate is an amino acid produced by neurons, which acts as a neurotransmitter between cells. While normal levels of glutamate are necessary to facilitate this cell-to-cell signaling, excess glutamate can be harmful.



Individuals who have experienced a traumatic brain injury, as well as those with neurodegenerative diseases like multiple sclerosis and amyotrophic lateral sclerosis, all show a build-up of glutamate. This excess glutamate accumulates outside the neurons, where central nervous system cells known as astrocytes work to regulate the amount of the neurotransmitter present. A glutamine transporter known as GLT-1 is used by the astrocytes to convert excess glutamate into glutamine, which acts as an energy source for cells.

“When a neuron fires, it releases glutamate into the space between itself and a nearby neuron,” said Wilson. “The nearby neuron detects this glutamate, which triggers a firing of the neuron. If the glutamate isn't cleared by GLT-1 then the neurons can't fire properly the next time and they start to die.”

In studying mice infected with toxoplasmosis gondii, the researchers found an increase in the levels of glutamate. The glutamate accumulation was explained by the impaired ability of astrocytes to clear the neurotransmitter in the presence of the parasite.

Wilson and her colleagues also found that GLT-1 expression was diminished in animals with toxoplasmosis, leading to a build-up of unconverted glutamate. This accumulation may cause neuronal cell death, and lead to the onset of neurodegenerative disease.

“These results suggest that in contrast to assuming chronic toxoplasmosis infection as quiescent and benign, we should be aware of the potential risk to normal neurological pathways and changes in brain chemistry,” said Wilson. “More direct and mechanistic research needs to be performed to understand the realities of this very common pathogen.”


Keywords: Toxoplasmosis, Neurodegenerative Disease, Neuron


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.